Status:
COMPLETED
Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Carcinoma, Non-small Cell Lung
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study will use imaging to look at tumor response to erlotinib (Part I) and the combination of erlotinib and dalotuzumab (Part II).
Eligibility Criteria
Inclusion
- Patient has locally advanced or metastatic stage IIIB/IV Non-small cell lung cancer
- Patient has measurable disease
- Patient has accessible tumor and consents to undergo a tumor biopsy \[Part II only\]
- Patient is 18 years of age or older
- Patient has a performance status of 0-2 on ECOG scale
- Women of childbearing potential have a negative pregnancy test
- Patients in Part I must: 1. be a female non-smoker with non-squamous histology who has had one or two prior systemic chemotherapies or 2. have documented EGFR mutation or EGFR gene amplification, regardless of demographic or clinical characteristics, who have had no more than two prior systemic chemotherapies.
- Patients in Part II must have had one or two chemotherapy regimens for recurrent or metastatic disease
Exclusion
- Patient has had chemotherapy within 2 weeks or biological therapy (e.g. bevacizumab) within 4 weeks
- Patient has not recovered from adverse events from previous therapy within 4 weeks
- Patient has received EGFR-TKI inhibitor/anti-EGFR mAb therapy
- Patient has received IGF1R-TKI inhibitor/anti-IGF1R mAB therapy
- Patient has untreated brain metastases
- Patient has had radiotherapy to a field that affects the chest or abdomen, or thoracic surgery within 3 months prior to entering the study
- Patient is taking part in another clinical study
- Patient abuses drugs or alcohol
- Patient is pregnant or breastfeeding
- Subject is HIV positive
- Patient has active hepatitis
- Patient is using growth hormone or growth hormone inhibitors
- Patient has poorly controlled diabetes mellitus
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT00729742
Start Date
February 1 2009
End Date
May 1 2011
Last Update
April 4 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.